Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06957431 · ClinicalTrials.gov registry record · Phase 1
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
A Phase 1 study of Advanced Leiomyosarcoma and Adipocytic Sarcoma, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06957431 is a Phase 1 study of Advanced Leiomyosarcoma and Adipocytic Sarcoma that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06957431, a Phase 1 study of Advanced Leiomyosarcoma and Adipocytic Sarcoma, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
Conditions Studied
Interventions
- DRUG Zanzalintinib
- DRUG Eribulin
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2033-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06957431
The ClinicalTrials.gov registry entry for NCT06957431 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Advanced Leiomyosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Zanzalintinib is the first listed.
NCT06957431 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06957431 about?
NCT06957431 is a clinical study titled "Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma". The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
What is the current status of trial NCT06957431?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-10-22. Estimated completion is 2033-10-31.
What conditions does trial NCT06957431 study?
This clinical trial studies the following conditions: Advanced Leiomyosarcoma, Adipocytic Sarcoma, Advanced Liposarcoma.
What interventions are being tested in trial NCT06957431?
The interventions under investigation include: Zanzalintinib (DRUG), Eribulin (DRUG).
Who is sponsoring clinical trial NCT06957431?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06957431 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.